IJSTR

International Journal of Scientific & Technology Research

Home Contact Us
ARCHIVES
ISSN 2277-8616











 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

IJSTR >> Volume 8 - Issue 11, November 2019 Edition



International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616



Microbiological Pattern of Secondary Infections, Standard Living Index and Pharmacoeconomic Analysis Among Tuberculosis Patients With Comorbidity

[Full Text]

 

AUTHOR(S)

Md Mujahid, Yatindra Kumar, parimalakrishnan. S , SP Singh

 

KEYWORDS

Secondary Infection Pathogens, Tuberculosis, Direct Medical Cost, Indirect Medical Cost, Standard Living Index

 

ABSTRACT

Aim: The aim of the present study is to determine the clinical, microbiological pattern of secondary infections and cost of illness for the tuberculosis subjects with and without hypertension. Method: The present study design is a cross-sectional observational prospective during January and December 2018 in a tertiary care teaching hospital located in Uttar Pradesh, India. Totally 68 patients were enrolled in the study. The subjects were divided into 2 groups: group I with TB only and group II with TB and hypertension. The data were collected from prescription and/ or interview with the subjects and Standard of Living Index was also estimated for the subjects. For all the subjects were subjected to either by Mantoux tuberculin skin test or sputum smear or both tests. Results: 27 subjects were having TB and hypertension in stage III (77.42%). 8% and 14% of subjects were having PTB and Extra PTB in group I and II respectively. 36% of subjects having S. aureus as secondary pathogens. 17 isolates carrying pathogens shown resistance to 14 various antibiotics in susceptibility and resistance test. Direct medical costs of group I was INR 5,6668.88 and group II was INR 11,677.08, which was high in both the groups when compared to indirect costs of both the groups; group I was INR 902.41 and in group II was INR 1012.68. Nearly 58.9% and 41.1% of subjects from the group I and group II, respectively, were lost their income during the treatment days. Conclusions: The present study concludes the following based on the findings, prevalence of TB is high in increased age, rural residents and unemployed in lower economic populations. Pulmonary TB cases are more than extrapulmonary TB and S. aureus was the most common secondary infection pathogen in isolates. Total medical cost and direct medical costs were higher in group II, whereas in the group I total medical cost was high. In both groups, a maximum number of subjects were on the medium scale of SLI. Treatment outcome was good in both groups around 70% in group I and 68% in group II among successfully completed subjects, which is as per the WHO standards.

 

REFERENCES

[1] Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003;16(3):463–496.
[2] National Institutes of Health (US); Biological Sciences Curriculum Study. NIH Curriculum Supplement Series [Internet]. Bethesda (MD): National Institutes of Health (US); 2007. Understanding Emerging and Re-emerging Infectious Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK20370/ - Accessed on 07.06.2019
[3] Delogu G, Sali M, Fadda G. The biology of mycobacterium tuberculosis infection. Mediterr J Hematol Infect Dis. 2013;5(1):e2013070.
[4] Sasindran SJ, Torrelles JB. Mycobacterium Tuberculosis Infection and Inflammation: what is Beneficial for the Host and for the Bacterium?. Front Microbiol. 2011;2:2.
[5] Glaziou P, Sismanidis C, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med. 2015;5(2):a017798.
[6] Floyd K, Glaziou P, Houben RMGJ, Sumner T, White RG, Raviglione M. Global tuberculosis targets and milestones set for 2016-2035: definition and rationale. Int J Tuberc Lung Dis. 2018;22(7):723–730.
[7] Agam Vora. Tuberculosis-A Tough Bug. Journal of The Association of Physicians of India, 2018; 66: 1.
[8] Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. Indian J Med Res. 2017;145(3):271–293.
[9] Central TB Division TB India 2016: RNTCP Status Report. Directorate of Health Services, Ministry of Health and Family Welfare, Nirman Bhavan, New Delhi.
[10] Maher D. Community contribution to TB care: policy and practice. Geneva, Switzerland. WHO, 2003.
[11] Amaryllis Langbang, Nabajit Deka, Hafizur Rahman and Devjyoti Kalita. A study on bacterial pathogens causing secondary infections in patients suffering from tuberculosis and their pattern of antibiotic sensitivity. Int. J. Curr. Microbiol. App. Sci.,2016; 5(8): 197 – 203.
[12] International Institute for Population Sciences: National Family Health Survey-II India 1998-99.2000 Mumbai.
[13] Khatri, GR. and T R. Frieden: Controlling tuberculosis in India. N Engl J Med 2002; 347(18):1420-1425.
[14] Zwarenstein, J. H. Schoeman, et al: Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998; 352(9137):1340-1353.
[15] Muniyandi. M, Rajeswari. R and Rani. B. Costs to patients with tuberculosis treated under DOTs Programme. Indian J Tuberc 2005; 52: 188-196.
[16] Prabhakar, R. Tuberculosis control in India-past, present and future.J Indian Med Assoc2000; 98(3): 123-125.
[17] Needham DM, Godfrey–Faunssett P, Foster SD: Barriers to tuberculosis control in urban Zambia: the economic impact and burden on patients prior to diagnosis. Int J Tuberc Lung Dis 1998; 2: 811–817.
[18] Kamolratanakul P, Sawert H, Kongsin S, et al: Economic impact of tuberculosis at household level. Int J Tuberc Lung Dis 1999; 3:596–602.
[19] World Health Organisation: An Expanded DOTS: Framework for effective tuberculosis control. World Health Organisation Geneva 2002.
[20] Muniyandi. M, Rajeswari R, R. Balasubramanian. Tuberculosis Control Programme - Is is pro poor. SAARC J Tuberc Lung Dis HIV/AIDS 2004; 1(1):1419.